

## **Supplementary Materials**

### **Article Title:**

Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis

### **Journal:**

Infection

### **Authors:**

Michael Ruzicka, Thomas Wimmer, Hans-Joachim Stemmler, Stephanie-Susanne Stecher, Hendrik Schulze-Koops, Fabian Hauck, Marion Subklewe, Michael von Bergwelt-Baildon, Karsten Spiekermann

### **Corresponding author:**

Dr. med. Michael Ruzicka

LMU University Hospital

Department of Medicine III, LMU Munich


Marchioninistrasse 15

81377 Munich, Germany

Email: michael.ruzicka@med.uni-muenchen.de

| Type of treatment                             | n (%) of patients |
|-----------------------------------------------|-------------------|
| <i>Glucocorticoids</i>                        | 28 (100)          |
| <i>IVIg</i>                                   | 12 (42.9)         |
| <i>Rituximab</i>                              | 10 (35.7)         |
| <i>Etoposide</i>                              | 10 (35.7)         |
| <i>Cyclosporine</i>                           | 5 (17.9)          |
| <i>Ruxolitinib</i>                            | 3 (10.1)          |
| <i>Anakinra</i>                               | 3 (10.1)          |
| <i>Cyclophosphamide</i>                       | 1 (3.6)           |
| <i>Plasmapheresis</i>                         | 2 (7.1)           |
| <i>EBV-specific CTLs</i>                      | 1 (3.6)           |
| <i>Allogeneic bone marrow transplantation</i> | 1 (3.6)           |
| Lines of treatment (n)                        | n (%) of patients |
| 1 ( <i>glucocorticoids only</i> )             | 7 (25.0)          |
| 2                                             | 6 (21.4)          |
| 3                                             | 10 (35.7)         |
| 4                                             | 3 (10.7)          |
| 5                                             | 0 (0.0)           |
| 6                                             | 0 (0.0)           |
| 7                                             | 1 (3.6)           |
| 8                                             | 1 (3.6)           |

**Supplementary Table 1. Treatment of iHLH patients**



**Supplementary figure 1. Full correlation matrix of clinical and laboratory parameters of iHLH patients.** The parameters assessed include iHLH patients' demographic, outcome, clinical and laboratory data. Pearson's correlation coefficients (r) between all variables are displayed. Positive correlations are indicated in blue, negative correlations in red, with color intensity reflecting correlation strength (range:  $r = -1$  to  $+1$ ). Asterisks indicate statistical significance (\* =  $p \leq 0.05$ ; \*\* =  $p \leq 0.01$ ; \*\*\* =  $p \leq 0.001$ ).